Earendil Labs secures USD787M in funding to accelerate AI-powered drug discovery platform

USA—Earendil Labs, an artificial intelligence-driven biotechnology company focused on advancing next-generation biologics, has announced a major funding round totaling USD787 million.

This substantial investment marks a pivotal moment for the Delaware-based firm, which has positioned itself at the forefront of using AI not merely as a research tool, but as a production engine for generating therapeutic programs at scale.

Building momentum with strategic investors

The funding round draws support from a diverse group of leading global investors, including Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, and the Biotech Development Fund—a joint initiative by Hillhouse and Pfizer.

Notably, pharmaceutical giant Sanofi has also participated in the round, further strengthening its existing relationship with the biotech company.

This combination of venture capital expertise and established pharmaceutical backing reflects confidence in Earendil’s technology and execution capability.

“This financing allows us to operate at a fundamentally different scale,” said Jian Peng, founder and chief executive officer of Earendil Labs.

“We can now advance multiple programs toward clinical development while simultaneously building an R&D organisation designed for sustained impact.”

The capital injection directly addresses Earendil’s ambition to progress its impressive arsenal of more than 40 programmes currently in various stages of development.

Advancing a robust pipeline

The crown jewel of Earendil’s pipeline is HXN-1001, a half-life extended antibody targeting anti-tumour necrosis factor-like cytokine 1A (TL1A).

The company recently completed Phase I testing of this therapy in healthy volunteers during July 2025 and now stands ready to enter Phase II clinical trials across inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis.

The therapeutic landscape for TL1A-targeting treatments remains competitive, with approximately 10 similar therapies currently under development for autoimmune conditions across preclinical and clinical stages.

Within this crowded field, two programmes have already demonstrated commercial potential.

Roche-owned Genentech’s afimkibart and MSD’s tulisokimart represent established competition, with market analysts projecting tulisokibart could generate approximately USD2 billion in annual sales by 2032.

Despite this competitive environment, Earendil’s AI-enabled approach provides a potential differentiation advantage through systematic and efficient candidate generation.

Beyond HXN-1001, Earendil intends to file investigational new drug applications for several preclinical assets during 2026 and 2027.

This aggressive expansion timeline underscores the company’s confidence in its AI platform and its capacity to move candidates through early-stage development efficiently.

Deepening the Sanofi partnership

Sanofi’s participation in this funding round represents more than financial support; it reflects an increasingly aligned partnership between the two organisations.

Earlier in January 2026, the companies concluded a broader strategic collaboration valued at USD2.56 billion to discover and develop therapeutic candidates targeting autoimmune and inflammatory conditions.

This agreement built upon an earlier blockbuster arrangement from April 2025, when Sanofi acquired rights to two of Earendil’s bispecific antibody programmes.

“Earendil Labs stands out for its ability to translate AI innovation into real, scalable R&D execution,” said Zavain Dar, founding managing partner at Dimension Capital.

“The team has demonstrated that AI can consistently generate high-quality biologics programmes and advance them toward clinical development.”

AI’s growing role in drug discovery

The investment in Earendil reflects a broader industry shift toward integrating artificial intelligence throughout the drug discovery and development process.

As traditional revenue streams face pressure from upcoming patent expirations—which threaten to eliminate approximately USD230 billion from the United States market between 2025 and 2030—pharmaceutical companies increasingly recognise AI as essential to maintaining pipeline productivity.

While many pharmaceutical firms choose to develop AI capabilities internally, strategic partnerships and acquisitions involving AI-focused technologies have surged dramatically.

During 2025 alone, 168 strategic alliances incorporating AI technology received formal announcements, according to industry data.

One notable example is a partnership between Eli Lilly and NVIDIA to build a supercomputer specifically designed to identify novel medicines, with additional applications in clinical planning, medical imaging, and manufacturing process optimisation.